Compare · AEON vs NVO
AEON vs NVO
Side-by-side comparison of AEON Biopharma Inc. (AEON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $213.34B, about 18581.3x AEON ($11.5M).
- Over the past year, AEON is down 69.4% and NVO is down 31.0% - NVO leads by 38.4 points.
- AEON has been more active in the news (9 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for AEON).
- Company
- AEON Biopharma Inc.
- Novo Nordisk A/S
- Price
- $0.25-2.39%
- $48.81+1.30%
- Market cap
- $11.5M
- $213.34B
- 1M return
- -65.73%
- +2.95%
- 1Y return
- -69.36%
- -31.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 9
- 5
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AEON
- AEON Biopharma Inc. filed SEC Form 8-K: Other Events
- SEC Form SCHEDULE 13G filed by AEON Biopharma Inc.
- AEON Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by AEON Biopharma Inc.
- AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
- SEC Form EFFECT filed by AEON Biopharma Inc.
- SEC Form S-1MEF filed by AEON Biopharma Inc.
- Amendment: SEC Form S-1/A filed by AEON Biopharma Inc.
- SEC Form S-1 filed by AEON Biopharma Inc.
- Director Thunen Shelley B was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S